Clinical Trial Details

NCT ID: NCT02446600
Date Last Changed: October 13, 2017

Overview

Research Study Summary

Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Research Study Title

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Purpose

This randomized phase III trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may stop the growth of ovarian, fallopian tube, or primary peritoneal cancer by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine hydrochloride, and pegylated liposomal doxorubicin hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether olaparib or cediranib maleate and olaparib is more effective than standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.

To Learn more

Recruitment Details

Phase
3
Gender
Female
Age
19 and up
Overall Status
Recruiting
Lead Sponsor
National Cancer Institute (NCI)
Duration
46 Months
Facility Type
N/A
Compensation

Eligibility

Female ages 19 Years and up

Inclusion Criteria:

  • Patients must have platinum-sensitive recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancers; patients with other (clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma) hihg-risk histologies are also eligible, provided that the patient has a known deleterious germline BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory; Note: Due to the long acceptance of germline BRCA testing through Myriad, Myriad testing will be accepted; if testing for germline BRCA is done by other organizations, documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) listing the mutation and confirming that the laboratory results showed a recognized germline deleterious BRCA1 or BRCA2 mutation or BRCA rearrangement is required; please collect a copy of Myriad or other BRCA mutational analysis (positive or VUS or negative) reports

  • Platinum-sensitive disease defined as no clinical or radiographic evidence of disease recurrence for > 6 months (or 182 days) after last receipt of platinum-based therapy

  • Patients must have had a complete clinical response to their prior line of platinum therapy and cannot have had progression through prior platinum-based therapy

  • Patients must have signed an approved informed consent and authorization permitting release of personal health information

  • Patients must have evaluable disease - defined as one of the following:

  • Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable disease OR

  • Evaluable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related) AND a cancer antigen 125 (CA125) that has doubled from the post-treatment nadir and is also greater than 2 times upper limit of normal (ULN)

  • Prior therapy:

  • Prior chemotherapy must have included a first-line platinum-based regimen with or without intravenous consolidation chemotherapy

  • Patients may have received an unlimited number of platinum-based therapies in the recurrent setting

  • Patients may have received up to 1 non-platinum-based line of therapy in the recurrent setting; prior hormonal therapy will not be considered to count as this non-platinum-based line

  • Patients may not have had a prior anti-angiogenic agent in the recurrent setting; prior use of bevacizumab in the upfront or upfront maintenance setting is allowed

  • Patients may not have previously received a poly adenosine diphosphate (ADP) ribose polymerase (PARP)-inhibitor

  • Prior hormonal-based therapy for ovarian, primary peritoneal, or fallopian tube cancer is acceptable

  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (Karnofsky > = 60%)

  • Absolute neutrophil count > = 1,500/mcL

  • Platelets > = 100,000/mcL

  • Hemoglobin > = 10 g/dL

  • Creatinine = < the institutional upper limit of normal (ULN) OR creatinine clearance > = 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

  • Urine protein: creatinine ratio (UPC) of = < 1 or less than or equal to 2+ proteinuria on two consecutive dipsticks taken no less than 1 week apart; UPC is the preferred test; patients with > = 2+ proteinuria on dipstick must also have a 24 hour urine collection demonstrating = < 500 mg over 24 hours

  • Total bilirubin = < 1.5 x the institutional ULN

  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) = < 3 times institutional ULN

  • Toxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTCAE v4.0); patients with long-standing stable grade 2 neuropathy may be considered after discussion with the overall principal investigator (PI), but may not receive carboplatin and paclitaxel as the reference regimen, if randomized to that arm

  • Patients must be able to swallow and retain oral medications and without gastrointestinal illnesses that would preclude absorption of cediranib or olaparib

  • Patients must have adequately controlled blood pressure (BP), with a BP no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for eligibility; patients must have a BP of = < 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to starting study; patients with hypertension may be managed with up to a maximum of three antihypertensive medications; it is strongly recommended that patients who are on three antihypertensive medications be followed by a cardiologist or blood pressure specialist for management of blood pressure while on protocol

  • Patients must be willing and able to check and record daily blood pressure readings; blood pressure cuffs will be provided to patients randomized to Arm III

  • Women of child-bearing potential must have a negative pregnancy test prior to study entry; women of child-bearing potential must agree to use two reliable forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 weeks after cediranib discontinuation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

  • Adequately controlled thyroid function, with no symptoms of thyroid dysfunction and thyroid stimulating hormone (TSH) within normal limits

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of starting treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients may not have had hormonal therapy within 2 weeks prior to entering the study; patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions

  • Patients may not be receiving any other investigational agents nor have participated in an investigational trial within the past 4 weeks

  • Patients may not be receiving any medication that may markedly affect renal function (e.g., vancomycin, amphotericin, pentamidine)

  • Patients may not have received prior treatment affecting the vascular endothelial growth factor (VEGF) pathway (including, but not limited to thalidomide, sunitinib, pazopanib, sorafenib, and nintedanib); bevacizumab used in the upfront setting in conjunction with chemotherapy and/or as maintenance to treat newly diagnosed disease will be allowed

  • Patients may not have previously received a PARP inhibitor

  • CA-125 only disease without RECIST 1.1 measurable or otherwise evaluable disease

  • Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans should not be included on this study; screening imaging to rule out brain metastases is not required for screening, but should be performed prior to study enrollment if clinically indicated; patients with treated brain metastases and resolution of any associated symptoms must demonstrate stable post-therapeutic imaging for at least 6 months following therapy prior to starting study drug

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib

  • Participants receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible; strong inhibitors and inducers of UGT/PgP should be used with caution

  • History of gastrointestinal perforation; patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed, there has been no evidence of fistula for at least 6 months, and patient is deemed to be at low risk of recurrent fistula

  • History of intra-abdominal abscess within the past 3 months

  • Current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months prior to starting study drugs

  • Dependency on intravenous (IV) hydration or total parenteral nutrition (TPN)

  • Any concomitant or prior invasive malignancies with the following curatively treated exceptions:

  • Treated limited stage basal cell or squamous cell carcinoma of the skin

  • Carcinoma in situ of the breast or cervix

  • Primary endometrial cancer meeting the following conditions: stage not greater than IA, grade 1 or 2, no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous/serous, clear cell, or other International Federation of Gynecology and Obstetrics (FIGO) grade 3 lesions

  • Prior cancer treated with a curative intent with no evidence of recurrent disease 3 years following diagnosis and judged by the investigator to be at low risk of recurrence

  • Patients with any of the following:

  • History of myocardial infarction within six months

  • Unstable angina

  • Resting electrocardiogram (ECG) with clinically significant abnormal findings

  • New York Heart Association (NYHA) classification of III or IV

  • If cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines

  • Patients with the following risk factors should have a baseline cardiac function assessment:

  • Prior treatment with anthracyclines

  • Prior treatment with trastuzumab

  • Prior central thoracic radiation therapy (RT), including RT to the heart

  • History of myocardial infarction within 6 to 12 months (patients with history of myocardial infarction within 6 months are excluded from the study)

  • Prior history of impaired cardiac function

  • History of stroke or transient ischemic attack within six months

  • Any prior history of hypertensive crisis or hypertensive encephalopathy

  • Clinically significant peripheral vascular disease or vascular disease (including aortic aneurysm or aortic dissection)

  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib

  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation with controlled ventricular rate), or psychiatric illness/social situations that would limit compliance with study requirements

  • Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib

  • Known human immunodeficiency virus (HIV)-positive individuals are ineligible

  • Patients may not use any complementary or alternative medicines including natural herbal products or folk remedies

  • No features suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated

  • No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUBCT)

Site Locations (337)

Country State City Zip Facility and Contact
United States Alabama Birmingham 35233 University of Alabama at Birmingham Cancer Center
Charles A. Leath
412-339-5294
Roster@nrgoncology.org

Charles A. Leath
Principal Investigator
United States Alabama Mobile 36688 University of South Alabama Mitchell Cancer Institute
Jennifer M. Scalici
251-445-9870
pfrancisco@usouthal.edu

Jennifer M. Scalici
Principal Investigator
United States Alaska Anchorage 99508 Alaska Women's Cancer Care
Benjamin B. Bridges
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Benjamin B. Bridges
Principal Investigator
United States Arizona Tucson 85704 Arizona Oncology Associates-West Orange Grove
Michael A. Bookman
520-797-4468

Michael A. Bookman
Principal Investigator
United States Arizona Tucson 85710 Arizona Oncology Associates-Wilmot
Michael A. Bookman
520-797-4468

Michael A. Bookman
Principal Investigator
United States Arkansas Little Rock 72205 University of Arkansas for Medical Sciences
Kristin K. Zorn
501-686-8274

Kristin K. Zorn
Principal Investigator
United States California Carmichael 95608 Mercy San Juan Medical Center
Delphine W. Ong
916-537-5237

Delphine W. Ong
Principal Investigator
United States California Greenbrae 94904 Marin Cancer Care Inc
Peter D. Eisenberg
415-925-5000
info@marinspecialtycare.com

Peter D. Eisenberg
Principal Investigator
United States California La Jolla 92093 UC San Diego Moores Cancer Center
Michael T. McHale
858-822-5354
cancercto@ucsd.edu

Michael T. McHale
Principal Investigator
United States California Los Angeles 90048 Cedars Sinai Medical Center
Bobbie J. Rimel
310-423-8965

Bobbie J. Rimel
Principal Investigator
United States California Mountain View 94040 Palo Alto Medical Foundation-Camino Division
Stacy D. D'Andre
415-209-2686
bernicl@sutterhealth.org

Stacy D. D'Andre
Principal Investigator
United States California Mountain View 94040 Palo Alto Medical Foundation-Gynecologic Oncology
Stacy D. D'Andre
415-209-2686
bernicl@sutterhealth.org

Stacy D. D'Andre
Principal Investigator
United States California Oakland 94611 Kaiser Permanente-Oakland
Ramey D. Littell
510-891-3400

Ramey D. Littell
Principal Investigator
United States California Palo Alto 94301 Palo Alto Medical Foundation Health Care
Stacy D. D'Andre
415-209-2686
bernicl@sutterhealth.org

Stacy D. D'Andre
Principal Investigator
United States California Pismo Beach 93449 PCR Oncology
John A. Ellerton
805-474-9143

John A. Ellerton
Principal Investigator
United States California Roseville 95661 Sutter Roseville Medical Center
Stacy D. D'Andre
415-209-2686
bernicl@sutterhealth.org

Stacy D. D'Andre
Principal Investigator
United States California Sacramento 95816 Mercy Medical Group
Delphine W. Ong
916-537-5237

Delphine W. Ong
Principal Investigator
United States California Sacramento 95816 Sutter Medical Center Sacramento
Stacy D. D'Andre
415-209-2686
bernicl@sutterhealth.org

Stacy D. D'Andre
Principal Investigator
United States California Sacramento 95825 Kaiser Permanente - Sacramento
Ramey D. Littell
510-891-3400

Ramey D. Littell
Principal Investigator
United States California San Francisco 94115 California Pacific Medical Center-Pacific Campus
Stacy D. D'Andre
415-209-2686
bernicl@sutterhealth.org

Stacy D. D'Andre
Principal Investigator
United States California San Francisco 94115 Kaiser Permanente-San Francisco
Ramey D. Littell
510-891-3400

Ramey D. Littell
Principal Investigator
United States California San Francisco 94158 UCSF Medical Center-Mission Bay
Stefanie M. Ueda
415-476-4082
Paul.Couey@ucsf.edu

Stefanie M. Ueda
Principal Investigator
United States California San Luis Obispo 93401 Pacific Central Coast Health Center-San Luis Obispo
Brian A. DiCarlo
Diane.DeVos-Schmidt@DignityHealth.org

Brian A. DiCarlo
Principal Investigator
United States California Santa Clara 95051 Kaiser Permanente Medical Center - Santa Clara
Ramey D. Littell
510-891-3400

Ramey D. Littell
Principal Investigator
United States California Santa Cruz 95065 Palo Alto Medical Foundation-Santa Cruz
Stacy D. D'Andre
415-209-2686
bernicl@sutterhealth.org

Stacy D. D'Andre
Principal Investigator
United States California Santa Rosa 95403 Sutter Pacific Medical Foundation
Stacy D. D'Andre
415-209-2686
bernicl@sutterhealth.org

Stacy D. D'Andre
Principal Investigator
United States California Sunnyvale 94086 Palo Alto Medical Foundation-Sunnyvale
Stacy D. D'Andre
415-209-2686
bernicl@sutterhealth.org

Stacy D. D'Andre
Principal Investigator
United States California Vallejo 94589 Kaiser Permanente-Vallejo
Ramey D. Littell
510-891-3400

Ramey D. Littell
Principal Investigator
United States California Walnut Creek 94596 Kaiser Permanente-Walnut Creek
Ramey D. Littell
510-891-3400

Ramey D. Littell
Principal Investigator
United States California Woodland 95695 Woodland Memorial Hospital
Delphine W. Ong
916-537-5237

Delphine W. Ong
Principal Investigator
United States Colorado Aurora 80012 Rocky Mountain Cancer Centers-Aurora
Keren Sturtz
303-777-2663
ccrp@co-cancerresearch.org

Keren Sturtz
Principal Investigator
United States Colorado Aurora 80045 University of Colorado Hospital
Saketh R. Guntupalli
720-848-0650

Saketh R. Guntupalli
Principal Investigator
United States Colorado Colorado Springs 80907 Penrose-Saint Francis Healthcare
Mehmet S. Copur
501-622-2100

Mehmet S. Copur
Principal Investigator
United States Colorado Colorado Springs 80909 Memorial Hospital Central
Saketh R. Guntupalli
720-848-0650

Saketh R. Guntupalli
Principal Investigator
United States Colorado Denver 80205 Kaiser Permanente-Franklin
Alexander Menter
303-777-2663
ccrp@co-cancerresearch.org

Alexander Menter
Principal Investigator
United States Colorado Denver 80220 Rocky Mountain Cancer Centers-Rose
Keren Sturtz
303-777-2663
ccrp@co-cancerresearch.org

Keren Sturtz
Principal Investigator
United States Colorado Fort Collins 80524 Poudre Valley Hospital
Saketh R. Guntupalli
720-848-0650

Saketh R. Guntupalli
Principal Investigator
United States Colorado Lafayette 80026 Kaiser Permanente-Rock Creek
Alexander Menter
303-777-2663
ccrp@co-cancerresearch.org

Alexander Menter
Principal Investigator
United States Colorado Littleton 80120 Rocky Mountain Cancer Centers-Littleton
Keren Sturtz
303-777-2663
ccrp@co-cancerresearch.org

Keren Sturtz
Principal Investigator
United States Colorado Lone Tree 80124 Kaiser Permanente-Lone Tree
Alexander Menter
303-777-2663
ccrp@co-cancerresearch.org

Alexander Menter
Principal Investigator
United States Colorado Lone Tree 80124 Rocky Mountain Cancer Centers-Sky Ridge
Keren Sturtz
303-777-2663
ccrp@co-cancerresearch.org

Keren Sturtz
Principal Investigator
United States Colorado Wheat Ridge 80033 SCL Health Lutheran Medical Center
Keren Sturtz
303-777-2663
ccrp@co-cancerresearch.org

Keren Sturtz
Principal Investigator
United States Connecticut Fairfield 06824 Smilow Cancer Hospital Care Center-Fairfield
Peter E. Schwartz
203-785-5702

Peter E. Schwartz
Principal Investigator
United States Connecticut Hartford 06102 Hartford Hospital
Amy K. Brown
860-224-5660

Amy K. Brown
Principal Investigator
United States Connecticut Hartford 06105 Smilow Cancer Hospital Care Center at Saint Francis
Peter E. Schwartz
203-785-5702

Peter E. Schwartz
Principal Investigator
United States Connecticut Middletown 06457 Middlesex Hospital
Susanna Hong
860-358-2058
beth_slifer@midhosp.org

Susanna Hong
Principal Investigator
United States Connecticut New Britain 06050 The Hospital of Central Connecticut
Amy K. Brown
860-224-5660

Amy K. Brown
Principal Investigator
United States Connecticut New Haven 06520 Yale University
Peter E. Schwartz
203-785-5702

Peter E. Schwartz
Principal Investigator
United States Connecticut Torrington 06790 Charlotte Hungerford Hospital Center for Cancer Care
Peter E. Schwartz
203-785-5702

Peter E. Schwartz
Principal Investigator
United States Connecticut Trumbull 06611 Smilow Cancer Hospital Care Center-Trumbull
Peter E. Schwartz
203-785-5702

Peter E. Schwartz
Principal Investigator
United States Delaware Newark 19713 Helen F Graham Cancer Center
Gregory A. Masters
302-733-6227

Gregory A. Masters
Principal Investigator
United States Delaware Newark 19718 Christiana Care Health System-Christiana Hospital
Gregory A. Masters
302-733-6227

Gregory A. Masters
Principal Investigator
United States Delaware Rehoboth Beach 19971 Beebe Health Campus
Gregory A. Masters
302-733-6227

Gregory A. Masters
Principal Investigator
United States Delaware Seaford 19973 Nanticoke Memorial Hospital
Gregory A. Masters
302-733-6227

Gregory A. Masters
Principal Investigator
United States District of Columbia Washington, D.C. 20016 Sibley Memorial Hospital
Deborah K. Armstrong
410-955-8804
jhcccro@jhmi.edu

Deborah K. Armstrong
Principal Investigator
United States Florida Gainesville 32610 University of Florida Health Science Center �� Gainesville
Merry J. Markham
352-273-8675
trials@cancer.ufl.edu

Merry J. Markham
Principal Investigator
United States Georgia Athens 30607 University Cancer and Blood Center LLC
Sharad A. Ghamande
706-721-1663
cancer@augusta.edu

Sharad A. Ghamande
Principal Investigator
United States Georgia Atlanta 30309 Piedmont Hospital
Adam W. Nowlan
404-425-7943
ORS@piedmont.org

Adam W. Nowlan
Principal Investigator
United States Georgia Atlanta 30342 Northside Hospital
Guilherme Henrique C. Cantuaria
404-303-3355

Guilherme Henrique C. Cantuaria
Principal Investigator
United States Georgia Decatur 30033 Dekalb Medical Center
Sharad A. Ghamande
706-721-1663
cancer@augusta.edu

Sharad A. Ghamande
Principal Investigator
United States Georgia Savannah 31404 Memorial University Medical Center
James J. Burke
912-350-8568

James J. Burke
Principal Investigator
United States Georgia Savannah 31405 Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Howard A. Zaren
912-819-5704

Howard A. Zaren
Principal Investigator
United States Hawaii Honolulu 96813 Queen's Medical Center
Michael E. Carney
808-586-2979

Michael E. Carney
Principal Investigator
United States Hawaii Honolulu 96826 Kapiolani Medical Center for Women and Children
Michael E. Carney
808-586-2979

Michael E. Carney
Principal Investigator
United States Idaho Boise 83706 Saint Alphonsus Cancer Care Center-Boise
J. R. Liu
208-367-7954

J. R. Liu
Principal Investigator
United States Idaho Boise 83712 Saint Luke's Mountain States Tumor Institute
Benjamin B. Bridges
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Benjamin B. Bridges
Principal Investigator
United States Idaho Fruitland 83619 Saint Luke's Mountain States Tumor Institute - Fruitland
Benjamin B. Bridges
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Benjamin B. Bridges
Principal Investigator
United States Idaho Meridian 83642 Saint Luke's Mountain States Tumor Institute - Meridian
Benjamin B. Bridges
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Benjamin B. Bridges
Principal Investigator
United States Idaho Nampa 83686 Saint Luke's Mountain States Tumor Institute - Nampa
Benjamin B. Bridges
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Benjamin B. Bridges
Principal Investigator
United States Illinois Aurora 60504 Rush - Copley Medical Center
Kendrith M. Rowland
630-978-6212
Cancer.Research@rushcopley.com

Kendrith M. Rowland
Principal Investigator
United States Illinois Bloomington 61704 Illinois CancerCare-Bloomington
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Canton 61520 Illinois CancerCare-Canton
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Carthage 62321 Illinois CancerCare-Carthage
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Centralia 62801 Centralia Oncology Clinic
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Chicago 60611 Northwestern University
Shohreh Shahabi
312-695-1301
cancer@northwestern.edu

Shohreh Shahabi
Principal Investigator
United States Illinois Chicago 60612 John H Stroger Jr Hospital of Cook County
Thomas E. Lad
312-864-6000

Thomas E. Lad
Principal Investigator
United States Illinois Chicago 60612 Rush University Medical Center
Summer B. Dewdney
312-942-5498
clinical_trials@rush.edu

Summer B. Dewdney
Principal Investigator
United States Illinois Chicago 60657 Presence Saint Joseph Hospital-Chicago
Ira A. Oliff
847-316-6994

Ira A. Oliff
Principal Investigator
United States Illinois Decatur 62526 Cancer Care Center of Decatur
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Decatur 62526 Decatur Memorial Hospital
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Effingham 62401 Crossroads Cancer Center
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Eureka 61530 Illinois CancerCare-Eureka
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Evanston 60201 NorthShore University HealthSystem-Evanston Hospital
Jean A. Hurteau
847-570-2109

Jean A. Hurteau
Principal Investigator
United States Illinois Galesburg 61401 Illinois CancerCare-Galesburg
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Geneva 60134 Northwestern Medicine Cancer Center Delnor
Barbara M. Buttin
630-315-1918
Claudine.Gamster@CadenceHealth.org

Barbara M. Buttin
Principal Investigator
United States Illinois Glenview 60026 NorthShore University HealthSystem-Glenbrook Hospital
Jean A. Hurteau
847-570-2109

Jean A. Hurteau
Principal Investigator
United States Illinois Highland Park 60035 NorthShore University HealthSystem-Highland Park Hospital
Jean A. Hurteau
847-570-2109

Jean A. Hurteau
Principal Investigator
United States Illinois Hinsdale 60521 Sudarshan K Sharma MD Limted-Gynecologic Oncology
Sudarshan K. Sharma
630-654-1790
info@hhoaltd.com

Sudarshan K. Sharma
Principal Investigator
United States Illinois Kewanee 61443 Illinois CancerCare-Kewanee Clinic
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Macomb 61455 Illinois CancerCare-Macomb
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Ottawa 61350 Illinois CancerCare-Ottawa Clinic
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Pekin 61554 Illinois CancerCare-Pekin
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Peoria 61615 Illinois CancerCare-Peoria
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Peru 61354 Illinois CancerCare-Peru
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Princeton 61356 Illinois CancerCare-Princeton
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Springfield 62702 Springfield Clinic
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Springfield 62781 Memorial Medical Center
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Swansea 62226 Cancer Care Specialists of Illinois-Swansea
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Illinois Warrenville 60555 Northwestern Medicine Cancer Center Warrenville
Barbara M. Buttin
630-315-1918
Claudine.Gamster@CadenceHealth.org

Barbara M. Buttin
Principal Investigator
United States Indiana Indianapolis 46260 Saint Vincent Hospital and Health Care Center
Michael J. Callahan
317-338-2194
research@stvincent.org

Michael J. Callahan
Principal Investigator
United States Iowa Clive 50325 Medical Oncology and Hematology Associates-West Des Moines
Mehmet S. Copur
501-622-2100

Mehmet S. Copur
Principal Investigator
United States Iowa Clive 50325 Mercy Cancer Center-West Lakes
Mehmet S. Copur
501-622-2100

Mehmet S. Copur
Principal Investigator
United States Iowa Des Moines 50309 Iowa Methodist Medical Center
Robert J. Behrens
515-239-2621

Robert J. Behrens
Principal Investigator
United States Iowa Des Moines 50309 Medical Oncology and Hematology Associates-Des Moines
Robert J. Behrens
515-239-2621

Robert J. Behrens
Principal Investigator
United States Iowa Des Moines 50314 Medical Oncology and Hematology Associates-Laurel
Mehmet S. Copur
501-622-2100

Mehmet S. Copur
Principal Investigator
United States Iowa Des Moines 50314 Mercy Medical Center - Des Moines
Mehmet S. Copur
501-622-2100

Mehmet S. Copur
Principal Investigator
United States Iowa Iowa City 52242 University of Iowa/Holden Comprehensive Cancer Center
David P. Bender
800-237-1225

David P. Bender
Principal Investigator
United States Iowa West Des Moines 50266 Mercy Medical Center-West Lakes
Mehmet S. Copur
501-622-2100

Mehmet S. Copur
Principal Investigator
United States Kansas Kansas City 66160 University of Kansas Cancer Center
Julia A. Chapman
913-945-7552
ctnursenav@kumc.edu

Julia A. Chapman
Principal Investigator
United States Kansas Pittsburg 66762 Via Christi Hospital-Pittsburg
Julia A. Chapman
913-945-7552
ctnursenav@kumc.edu

Julia A. Chapman
Principal Investigator
United States Kansas Topeka 66606 Cotton O'Neil Cancer Center / Stormont Vail Health
Mehmood H. Hashmi
913-945-7552
ctnursenav@kumc.edu

Mehmood H. Hashmi
Principal Investigator
United States Kansas Wichita 67208 Associates In Womens Health
Shaker R. Dakhil
316-268-5374

Shaker R. Dakhil
Principal Investigator
United States Kansas Wichita 67214 Via Christi Regional Medical Center
Shaker R. Dakhil
316-268-5374

Shaker R. Dakhil
Principal Investigator
United States Kentucky Lexington 40536 University of Kentucky/Markey Cancer Center
Frederick R. Ueland
859-257-3379

Frederick R. Ueland
Principal Investigator
United States Kentucky Louisville 40202 Norton Hospital Pavilion and Medical Campus
Mary E. Gordinier
502-629-3465

Mary E. Gordinier
Principal Investigator
United States Kentucky Louisville 40207 Norton Suburban Hospital and Medical Campus
Mary E. Gordinier
502-629-3465

Mary E. Gordinier
Principal Investigator
United States Kentucky Louisville 40241 Norton Brownsboro Hospital and Medical Campus
Mary E. Gordinier
502-629-3465

Mary E. Gordinier
Principal Investigator
United States Louisiana Baton Rouge 70809 Mary Bird Perkins Cancer Center
Patricia S. Braly
225-215-1353
clinicalresearch@marybird.com

Patricia S. Braly
Principal Investigator
United States Louisiana Baton Rouge 70817 Woman's Hospital
M. G. Fort
412-339-5294
Roster@nrgoncology.org

M. G. Fort
Principal Investigator
United States Louisiana Covington 70433 Women's Cancer Care-Covington
Patricia S. Braly
225-215-1353
clinicalresearch@marybird.com

Patricia S. Braly
Principal Investigator
United States Louisiana New Orleans 70121 Ochsner Medical Center Jefferson
Katrina S. Wade
504-842-3708

Katrina S. Wade
Principal Investigator
United States Maine Bangor 04401 Eastern Maine Medical Center
Thomas H. Openshaw
207-973-4274

Thomas H. Openshaw
Principal Investigator
United States Maine Brewer 04412 Lafayette Family Cancer Center-EMMC
Thomas H. Openshaw
207-973-4274

Thomas H. Openshaw
Principal Investigator
United States Maine Scarborough 04074 Maine Medical Center- Scarborough Campus
Christopher J. Darus
207-885-7565

Christopher J. Darus
Principal Investigator
United States Maryland Baltimore 21204 Greater Baltimore Medical Center
Paul Celano
443-849-3706

Paul Celano
Principal Investigator
United States Maryland Baltimore 21237 MedStar Franklin Square Medical Center/Weinberg Cancer Institute
Pallavi P. Kumar
443-777-7364

Pallavi P. Kumar
Principal Investigator
United States Maryland Baltimore 21287 Johns Hopkins University/Sidney Kimmel Cancer Center
Deborah K. Armstrong
410-955-8804
jhcccro@jhmi.edu

Deborah K. Armstrong
Principal Investigator
United States Maryland Easton 21601 The Memorial Hospital at Easton
Mary S. De Shields
410-820-6800 ext. 108
srichter@shorehealth.org

Mary S. De Shields
Principal Investigator
United States Massachusetts Boston 02111 Tufts Medical Center
Young B. Kim
617-636-5000
ContactUsCancerCenter@TuftsMedicalCenter.org

Young B. Kim
Principal Investigator
United States Massachusetts Boston 02115 Brigham and Women's Hospital
Joyce F. Liu
877-442-3324

Joyce F. Liu
Principal Investigator
United States Massachusetts Boston 02215 Dana-Farber Cancer Institute
Joyce F. Liu
877-442-3324

Joyce F. Liu
Principal Investigator
United States Massachusetts Burlington 01805 Lahey Hospital and Medical Center
Corrine L. Zarwan
781-744-8027

Corrine L. Zarwan
Principal Investigator
United States Michigan Ann Arbor 48106-0995 Saint Joseph Mercy Hospital
J. R. Liu
208-367-7954

J. R. Liu
Principal Investigator
United States Michigan Ann Arbor 48109 University of Michigan Comprehensive Cancer Center
Carolyn M. Johnston
734-712-3456

Carolyn M. Johnston
Principal Investigator
United States Michigan Brownstown Charter Township 48183 Henry Ford Cancer Institute¿Downriver
Thomas E. Buekers
313-916-1784

Thomas E. Buekers
Principal Investigator
United States Michigan Clinton 48038 Henry Ford Macomb Hospital-Clinton Township
Thomas E. Buekers
313-916-1784

Thomas E. Buekers
Principal Investigator
United States Michigan Detroit 48201 Wayne State University/Karmanos Cancer Institute
Robert T. Morris
313-576-9363

Robert T. Morris
Principal Investigator
United States Michigan Detroit 48202 Henry Ford Hospital
Thomas E. Buekers
313-916-1784

Thomas E. Buekers
Principal Investigator
United States Michigan Farmington Hills 48334 Weisberg Cancer Treatment Center
Robert T. Morris
313-576-9363

Robert T. Morris
Principal Investigator
United States Michigan Flint 48502 Hurley Medical Center
J. R. Liu
208-367-7954

J. R. Liu
Principal Investigator
United States Michigan Flint 48503 Genesys Hurley Cancer Institute
J. R. Liu
208-367-7954

J. R. Liu
Principal Investigator
United States Michigan Grand Rapids 49503 Spectrum Health at Butterworth Campus
Kathleen J. Yost
616-391-1230
crcwm-regulatory@crcwm.org

Kathleen J. Yost
Principal Investigator
United States Michigan Kalamazoo 49007 West Michigan Cancer Center
Kathleen J. Yost
616-391-1230
crcwm-regulatory@crcwm.org

Kathleen J. Yost
Principal Investigator
United States Michigan Lansing 48912 Sparrow Hospital
J. R. Liu
208-367-7954

J. R. Liu
Principal Investigator
United States Michigan Pontiac 48341 Saint Joseph Mercy Oakland
J. R. Liu
208-367-7954

J. R. Liu
Principal Investigator
United States Michigan Southfield 48075 Providence Hospital-Southfield Cancer Center
Vinay K. Malviya
248-849-5337
jaswinder.grewal@stjohn.org

Vinay K. Malviya
Principal Investigator
United States Michigan Traverse City 49684 Munson Medical Center
Kathleen J. Yost
616-391-1230
crcwm-regulatory@crcwm.org

Kathleen J. Yost
Principal Investigator
United States Michigan West Bloomfield Township 48322 Henry Ford West Bloomfield Hospital
Thomas E. Buekers
313-916-1784

Thomas E. Buekers
Principal Investigator
United States Minnesota Bemidji 56601 Sanford Clinic North-Bemidgi
Maria C. Bell
218-333-5000

Maria C. Bell
Principal Investigator
United States Minnesota Burnsville 55337 Fairview Ridges Hospital
Rachel E. Lerner
952-993-1517
mmcorc@healthpartners.com

Rachel E. Lerner
Principal Investigator
United States Minnesota Coon Rapids 55433 Mercy Hospital
Rachel E. Lerner
952-993-1517
mmcorc@healthpartners.com

Rachel E. Lerner
Principal Investigator
United States Minnesota Edina 55435 Fairview-Southdale Hospital
Rachel E. Lerner
952-993-1517
mmcorc@healthpartners.com

Rachel E. Lerner
Principal Investigator
United States Minnesota Mankato 56001 Mayo Clinic Health Systems-Mankato
Gretchen E. Glaser
855-776-0015

Gretchen E. Glaser
Principal Investigator
United States Minnesota Maple Grove 55369 Fairview Maple Grove Medical Center
Rachel E. Lerner
952-993-1517
mmcorc@healthpartners.com

Rachel E. Lerner
Principal Investigator
United States Minnesota Maplewood 55109 Saint John's Hospital - Healtheast
Rachel E. Lerner
952-993-1517
mmcorc@healthpartners.com

Rachel E. Lerner
Principal Investigator
United States Minnesota Minneapolis 55407 Abbott-Northwestern Hospital
Rachel E. Lerner
952-993-1517
mmcorc@healthpartners.com

Rachel E. Lerner
Principal Investigator
United States Minnesota Minneapolis 55455 University of Minnesota/Masonic Cancer Center
Melissa A. Geller
952-993-1517
mmcorc@healthpartners.com

Melissa A. Geller
Principal Investigator
United States Minnesota Rochester 55905 Mayo Clinic
Gretchen E. Glaser
855-776-0015

Gretchen E. Glaser
Principal Investigator
United States Minnesota Saint Louis Park 55416 Park Nicollet Clinic - Saint Louis Park
Rachel E. Lerner
952-993-1517
mmcorc@healthpartners.com

Rachel E. Lerner
Principal Investigator
United States Minnesota Saint Paul 55101 Regions Hospital
Rachel E. Lerner
952-993-1517
mmcorc@healthpartners.com

Rachel E. Lerner
Principal Investigator
United States Minnesota Saint Paul 55102 United Hospital
Rachel E. Lerner
952-993-1517
mmcorc@healthpartners.com

Rachel E. Lerner
Principal Investigator
United States Minnesota Shakopee 55379 Saint Francis Regional Medical Center
Rachel E. Lerner
952-993-1517
mmcorc@healthpartners.com

Rachel E. Lerner
Principal Investigator
United States Minnesota Woodbury 55125 Minnesota Oncology Hematology PA-Woodbury
Rachel E. Lerner
952-993-1517
mmcorc@healthpartners.com

Rachel E. Lerner
Principal Investigator
United States Mississippi Jackson 39216 Saint Dominic-Jackson Memorial Hospital
Donald P. Seago
601-200-3300

Donald P. Seago
Principal Investigator
United States Mississippi Jackson 39216 University of Mississippi Medical Center
Kelly J. Wilkinson
601-815-6700

Kelly J. Wilkinson
Principal Investigator
United States Missouri Cape Girardeau 63703 Saint Francis Medical Center
James L. Wade
309-243-3605

James L. Wade
Principal Investigator
United States Missouri Joplin 64804 Mercy Hospital-Joplin
Jay W. Carlson
888-221-4849

Jay W. Carlson
Principal Investigator
United States Missouri Saint Louis 63110 Barnes-Jewish Hospital
David G. Mutch
800-600-3606
info@siteman.wustl.edu

David G. Mutch
Principal Investigator
United States Missouri Saint Louis 63110 Washington University School of Medicine
David G. Mutch
800-600-3606
info@siteman.wustl.edu

David G. Mutch
Principal Investigator
United States Missouri Springfield 65804 Mercy Hospital Springfield
Jay W. Carlson
888-221-4849

Jay W. Carlson
Principal Investigator
United States Missouri Springfield 65807 CoxHealth South Hospital
Jay W. Carlson
888-221-4849

Jay W. Carlson
Principal Investigator
United States Montana Billings 59101 Billings Clinic Cancer Center
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

Benjamin T. Marchello
Principal Investigator
United States Montana Great Falls 59405 Benefis Healthcare- Sletten Cancer Institute
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

Benjamin T. Marchello
Principal Investigator
United States Montana Kalispell 59901 Kalispell Regional Medical Center
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

Benjamin T. Marchello
Principal Investigator
United States Montana Missoula 59804 Community Medical Hospital
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

Benjamin T. Marchello
Principal Investigator
United States Nebraska Grand Island 68803 CHI Health Saint Francis
Mehmet S. Copur
501-622-2100

Mehmet S. Copur
Principal Investigator
United States Nebraska Kearney 68847 CHI Health Good Samaritan
Mehmet S. Copur
501-622-2100

Mehmet S. Copur
Principal Investigator
United States Nebraska Omaha 68114 Nebraska Methodist Hospital
Brent J. Tierney
402-559-6941
unmcrsa@unmc.edu

Brent J. Tierney
Principal Investigator
United States Nebraska Omaha 68124 Alegent Health Bergan Mercy Medical Center
Mehmet S. Copur
501-622-2100

Mehmet S. Copur
Principal Investigator
United States Nebraska Omaha 68130 Alegent Health Lakeside Hospital
Mehmet S. Copur
501-622-2100

Mehmet S. Copur
Principal Investigator
United States Nevada Las Vegas 89169 Women's Cancer Center of Nevada
Nicola M. Spirtos
415-209-2686
bernicl@sutterhealth.org

Nicola M. Spirtos
Principal Investigator
United States New Hampshire Dover 03820 Wentworth-Douglass Hospital
John O. Schorge
877-726-5130

John O. Schorge
Principal Investigator
United States New Hampshire Lebanon 03756 Dartmouth Hitchcock Medical Center
Leslie R. DeMars
800-639-6918
cancer.research.nurse@dartmouth.edu

Leslie R. DeMars
Principal Investigator
United States New Hampshire Nashua 03063 Norris Cotton Cancer Center-Nashua
Leslie R. DeMars
800-639-6918
cancer.research.nurse@dartmouth.edu

Leslie R. DeMars
Principal Investigator
United States New Jersey Basking Ridge 07920 Memorial Sloan Kettering Basking Ridge
William P. Tew
212-639-7202

William P. Tew
Principal Investigator
United States New Jersey Camden 08103 Cooper Hospital University Medical Center
David P. Warshal
856-325-6757

David P. Warshal
Principal Investigator
United States New Jersey Englewood 07631 Englewood Hospital and Medical Center
Nimesh P. Nagarsheth
201-894-3456

Nimesh P. Nagarsheth
Principal Investigator
United States New Jersey Voorhees 08043 MD Anderson Cancer Center at Cooper-Voorhees
David P. Warshal
856-325-6757

David P. Warshal
Principal Investigator
United States New Mexico Albuquerque 87102 University of New Mexico Cancer Center
Carolyn Y. Muller
505-925-0366
LByatt@nmcca.org

Carolyn Y. Muller
Principal Investigator
United States New Mexico Albuquerque 87106 Southwest Gynecologic Oncology Associates Inc
Carolyn Y. Muller
505-925-0366
LByatt@nmcca.org

Carolyn Y. Muller
Principal Investigator
United States New Mexico Las Cruces 88011 Memorial Medical Center - Las Cruces
Carolyn Y. Muller
505-925-0366
LByatt@nmcca.org

Carolyn Y. Muller
Principal Investigator
United States New York Brooklyn 11203 State University of New York Downstate Medical Center
Ovadia Abulafia
718-613-8324
seema.chittalae@downstate.edu

Ovadia Abulafia
Principal Investigator
United States New York Buffalo 14263 Roswell Park Cancer Institute
Shashikant B. Lele
877-275-7724

Shashikant B. Lele
Principal Investigator
United States New York Commack 11725 Memorial Sloan Kettering Commack
William P. Tew
212-639-7202

William P. Tew
Principal Investigator
United States New York Harrison 10604 Memorial Sloan Kettering Westchester
William P. Tew
212-639-7202

William P. Tew
Principal Investigator
United States New York New York 10016 Laura and Isaac Perlmutter Cancer Center at NYU Langone
Bhavana Pothuri
212-263-4434
prmc.coordinator@nyumc.org

Bhavana Pothuri
Principal Investigator
United States New York New York 10065 Memorial Sloan-Kettering Cancer Center
William P. Tew
212-639-7202

William P. Tew
Principal Investigator
United States New York Rochester 14642 University of Rochester
Richard G. Moore
585-341-8113

Richard G. Moore
Principal Investigator
United States New York Rockville Centre 11570 Memorial Sloan Kettering Rockville Centre
William P. Tew
212-639-7202

William P. Tew
Principal Investigator
United States New York The Bronx 10461 Montefiore Medical Center-Einstein Campus
Nicole S. Nevadunsky
718-904-2730
aecc@aecom.yu.edu

Nicole S. Nevadunsky
Principal Investigator
United States New York White Plains 10601 Dickstein Cancer Treatment Center
Dan Costin
914-849-7582
mcortese@wphospital.org

Dan Costin
Principal Investigator
United States North Carolina Chapel Hill 27599 UNC Lineberger Comprehensive Cancer Center
Linda Van Le
877-668-0683
cancerclinicaltrials@med.unc.edu

Linda Van Le
Principal Investigator
United States North Carolina Durham 27710 Duke University Medical Center
Angeles A. Secord
888-275-3853

Angeles A. Secord
Principal Investigator
United States North Carolina Goldsboro 27534 Southeastern Medical Oncology Center-Goldsboro
James N. Atkins
252-399-7491

James N. Atkins
Principal Investigator
United States North Carolina Jacksonville 28546 Southeastern Medical Oncology Center-Jacksonville
James N. Atkins
252-399-7491

James N. Atkins
Principal Investigator
United States North Carolina Pinehurst 28374 FirstHealth of the Carolinas-Moore Regional Hosiptal
Michael J. Sundborg
910-715-2200

Michael J. Sundborg
Principal Investigator
United States North Carolina Raleigh 27609 Duke Raleigh Hospital
Angeles A. Secord
888-275-3853

Angeles A. Secord
Principal Investigator
United States North Carolina Wilmington 28401 New Hanover Regional Medical Center/Zimmer Cancer Center
Walter H. Gajewski
910-342-3000

Walter H. Gajewski
Principal Investigator
United States North Carolina Wilson 27893 Southeastern Medical Oncology Center-Wilson
James N. Atkins
252-399-7491

James N. Atkins
Principal Investigator
United States North Carolina Winston-Salem 27157 Wake Forest University Health Sciences
Samuel S. Lentz
336-713-6771

Samuel S. Lentz
Principal Investigator
United States North Dakota Bismarck 58501 Sanford Bismarck Medical Center
Maria C. Bell
218-333-5000

Maria C. Bell
Principal Investigator
United States North Dakota Fargo 58122 Roger Maris Cancer Center
Maria C. Bell
218-333-5000

Maria C. Bell
Principal Investigator
United States North Dakota Fargo 58122 Sanford Broadway Medical Center
Maria C. Bell
218-333-5000

Maria C. Bell
Principal Investigator
United States North Dakota Fargo 58122 Sanford Clinic North-Fargo
Maria C. Bell
218-333-5000

Maria C. Bell
Principal Investigator
United States North Dakota Minot 58701 Trinity Cancer Care Center
Stephen N. Makoni
800-862-0005

Stephen N. Makoni
Principal Investigator
United States Ohio Akron 44304 Summa Akron City Hospital/Cooper Cancer Center
Stephen J. Andrews
330-615-4132

Stephen J. Andrews
Principal Investigator
United States Ohio Akron 44307 Akron General Medical Center
Esther H. Rehmus
330-344-6348

Esther H. Rehmus
Principal Investigator
United States Ohio Cincinnati 45219 University of Cincinnati/Barrett Cancer Center
Eric L. Eisenhauer
800-293-5066
Jamesline@osumc.edu

Eric L. Eisenhauer
Principal Investigator
United States Ohio Cincinnati 45220 Good Samaritan Hospital - Cincinnati
Mehmet S. Copur
501-622-2100

Mehmet S. Copur
Principal Investigator
United States Ohio Cincinnati 45247 TriHealth Cancer Institute-Westside
Mehmet S. Copur
501-622-2100

Mehmet S. Copur
Principal Investigator
United States Ohio Cleveland 44106 Case Western Reserve University
Steven E. Waggoner
800-641-2422

Steven E. Waggoner
Principal Investigator
United States Ohio Cleveland 44109 MetroHealth Medical Center
Kimberly E. Resnick
800-641-2422

Kimberly E. Resnick
Principal Investigator
United States Ohio Cleveland 44111 Cleveland Clinic Cancer Center/Fairview Hospital
Peter G. Rose
866-223-8100

Peter G. Rose
Principal Investigator
United States Ohio Cleveland 44195 Cleveland Clinic Foundation
Peter G. Rose
866-223-8100

Peter G. Rose
Principal Investigator
United States Ohio Columbus 43210 Ohio State University Comprehensive Cancer Center
David M. O'Malley
800-293-5066
Jamesline@osumc.edu

David M. O'Malley
Principal Investigator
United States Ohio Columbus 43214 Columbus Oncology and Hematology Associates Inc
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

Timothy D. Moore
Principal Investigator
United States Ohio Columbus 43214 Riverside Methodist Hospital
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

Timothy D. Moore
Principal Investigator
United States Ohio Columbus 43219 The Mark H Zangmeister Center
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

Timothy D. Moore
Principal Investigator
United States Ohio Dayton 45405 Grandview Hospital
Thomas J. Reid
513-558-4553
uchealthnews@uc.edu

Thomas J. Reid
Principal Investigator
United States Ohio Findlay 45840 Orion Cancer Care
Howard M. Gross
937-775-1350
som_dcop@wright.edu

Howard M. Gross
Principal Investigator
United States Ohio Mayfield Heights 44124 Hillcrest Hospital Cancer Center
Peter G. Rose
866-223-8100

Peter G. Rose
Principal Investigator
United States Ohio Mentor 44060 Lake University Ireland Cancer Center
Steven E. Waggoner
800-641-2422

Steven E. Waggoner
Principal Investigator
United States Ohio Sylvania 43560 Flower Hospital
Adam C. Walter
419-824-1842

Adam C. Walter
Principal Investigator
United States Ohio Toledo 43606 The Toledo Hospital/Toledo Children's Hospital
Adam C. Walter
419-824-1842

Adam C. Walter
Principal Investigator
United States Ohio Wright-Patterson Air Force Base 45433-5529 Wright-Patterson Medical Center
Susannah C. Cooper
937-775-1350
som_dcop@wright.edu

Susannah C. Cooper
Principal Investigator
United States Oklahoma Oklahoma City 73104 University of Oklahoma Health Sciences Center
Robert S. Mannel
405-271-8777
ou-clinical-trials@ouhsc.edu

Robert S. Mannel
Principal Investigator
United States Oklahoma Tulsa 74146 Oklahoma Cancer Specialists and Research Institute-Tulsa
Robert S. Mannel
405-271-8777
ou-clinical-trials@ouhsc.edu

Robert S. Mannel
Principal Investigator
United States Oregon Bend 97701 Saint Charles Health System
Benjamin B. Bridges
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Benjamin B. Bridges
Principal Investigator
United States Oregon Eugene 97401 Willamette Valley Cancer Center
Michael A. Bookman
520-797-4468

Michael A. Bookman
Principal Investigator
United States Oregon Gresham 97030 Legacy Mount Hood Medical Center
Colleen C. McCormick
800-220-4937
cancer@lhs.org

Colleen C. McCormick
Principal Investigator
United States Oregon Portland 97210 Legacy Good Samaritan Hospital and Medical Center
Colleen C. McCormick
800-220-4937
cancer@lhs.org

Colleen C. McCormick
Principal Investigator
United States Oregon Portland 97227 Kaiser Permanente Northwest
Abdul H. Mansoor
503-335-2400

Abdul H. Mansoor
Principal Investigator
United States Pennsylvania Abington 19001 Abington Memorial Hospital
Joel I. Sorosky
215-481-2402

Joel I. Sorosky
Principal Investigator
United States Pennsylvania Bethlehem 18015 Saint Luke's University Hospital-Bethlehem Campus
Nicholas P. Taylor
412-339-5294
Roster@nrgoncology.org

Nicholas P. Taylor
Principal Investigator
United States Pennsylvania Danville 17822 Geisinger Medical Center
Radhika P. Gogoi
570-271-5251

Radhika P. Gogoi
Principal Investigator
United States Pennsylvania Ephrata 17522 Ephrata Cancer Center
Mark A. Miller
877-441-7957

Mark A. Miller
Principal Investigator
United States Pennsylvania Gettysburg 17325 Adams Cancer Center
Mark A. Miller
877-441-7957

Mark A. Miller
Principal Investigator
United States Pennsylvania Lancaster 17604 Lancaster General Hospital
Caitlin J. Stashwick
717-544-5511

Caitlin J. Stashwick
Principal Investigator
United States Pennsylvania Philadelphia 19103 NRG Oncology
Joyce F. Liu
617-632-8927
joyce_liu@dfci.harvard.edu

Joyce F. Liu
Principal Investigator
United States Pennsylvania Philadelphia 19104 University of Pennsylvania/Abramson Cancer Center
Emily M. Ko
877-668-0683
cancerclinicaltrials@med.unc.edu

Emily M. Ko
Principal Investigator
United States Pennsylvania Philadelphia 19107 Thomas Jefferson University Hospital
Russell J. Schilder
215-955-6084

Russell J. Schilder
Principal Investigator
United States Pennsylvania Pittsburgh 15224 West Penn Hospital
Thomas C. Krivak
877-284-2000

Thomas C. Krivak
Principal Investigator
United States Pennsylvania Pittsburgh 15232 University of Pittsburgh Cancer Institute (UPCI)
Alexander B. Olawaiye
412-647-2811

Alexander B. Olawaiye
Principal Investigator
United States Pennsylvania Sayre 18840 Guthrie Medical Group PC-Robert Packer Hospital
Philip A. Lowry
800-836-0388

Philip A. Lowry
Principal Investigator
United States Pennsylvania Selinsgrove 17870 Geisinger Medical Oncology-Selinsgrove
Radhika P. Gogoi
570-271-5251

Radhika P. Gogoi
Principal Investigator
United States Pennsylvania West Reading 19611 Reading Hospital
Terrence P. Cescon
610-988-9323

Terrence P. Cescon
Principal Investigator
United States Pennsylvania Williamsport 17701 UPMC Susquehanna
Warren L. Robinson
412-647-8073

Warren L. Robinson
Principal Investigator
United States Pennsylvania York 17403 WellSpan Health-York Hospital
Mark A. Miller
877-441-7957

Mark A. Miller
Principal Investigator
United States Rhode Island Providence 02905 Women and Infants Hospital
Paul A. DiSilvestro
401-274-1122

Paul A. DiSilvestro
Principal Investigator
United States South Carolina Anderson 29621 AnMed Health Cancer Center
David Griffin
800-486-5941

David Griffin
Principal Investigator
United States South Carolina Charleston 29425 Medical University of South Carolina
Whitney S. Graybill
843-792-9321

Whitney S. Graybill
Principal Investigator
United States South Carolina Greenville 29601 Saint Francis Hospital
David Griffin
800-486-5941

David Griffin
Principal Investigator
United States South Carolina Greenville 29605 Greenville Health System Cancer Institute-Faris
Jeffrey W. Elder
864-679-3966

Jeffrey W. Elder
Principal Investigator
United States South Carolina Greenville 29607 Saint Francis Cancer Center
David Griffin
800-486-5941

David Griffin
Principal Investigator
United States South Carolina Hilton Head Island 29926-3827 South Carolina Cancer Specialists PC
Howard A. Zaren
912-819-5704

Howard A. Zaren
Principal Investigator
United States South Dakota Rapid City 57701 Rapid City Regional Hospital
Michael J. Swartz
605-716-3982
research@rcrh.org

Michael J. Swartz
Principal Investigator
United States South Dakota Sioux Falls 57104 Sanford Cancer Center-Oncology Clinic
Maria C. Bell
218-333-5000

Maria C. Bell
Principal Investigator
United States South Dakota Sioux Falls 57105 Avera Cancer Institute
David C. Starks
888-634-7268
oncregulatory@avera.org

David C. Starks
Principal Investigator
United States South Dakota Sioux Falls 57117-5134 Sanford USD Medical Center - Sioux Falls
Maria C. Bell
218-333-5000

Maria C. Bell
Principal Investigator
United States Tennessee Johnson City 37604 Wellmont Medical Associates Oncology and Hematology-Johnson City
Asheesh Shipstone
423-224-5593

Asheesh Shipstone
Principal Investigator
United States Tennessee Kingsport 37660 Wellmont Holston Valley Hospital and Medical Center
Asheesh Shipstone
423-224-5593

Asheesh Shipstone
Principal Investigator
United States Tennessee Kingsport 37660 Wellmont Medical Associates Oncology and Hematology-Kingsport
Asheesh Shipstone
423-224-5593

Asheesh Shipstone
Principal Investigator
United States Tennessee Knoxville 37916 Thompson Cancer Survival Center
Brook A. Saunders
865-331-1812

Brook A. Saunders
Principal Investigator
United States Tennessee Knoxville 37932 Thompson Cancer Survival Center - West
Brook A. Saunders
865-331-1812

Brook A. Saunders
Principal Investigator
United States Tennessee Nashville 37232 Vanderbilt University/Ingram Cancer Center
Marta A. Crispens
800-811-8480

Marta A. Crispens
Principal Investigator
United States Texas Austin 78731 Texas Oncology - Central Austin Cancer Center
Michael A. Bookman
520-797-4468

Michael A. Bookman
Principal Investigator
United States Texas Austin 78745 Texas Oncology - South Austin Cancer Center
Michael A. Bookman
520-797-4468

Michael A. Bookman
Principal Investigator
United States Texas Bedford 76022 Texas Oncology Bedford
Michael A. Bookman
520-797-4468

Michael A. Bookman
Principal Investigator
United States Texas Dallas 75235 Parkland Memorial Hospital
Jayanthi S. Lea
214-590-5582

Jayanthi S. Lea
Principal Investigator
United States Texas Dallas 75390 UT Southwestern/Simmons Cancer Center-Dallas
Jayanthi S. Lea
214-590-5582

Jayanthi S. Lea
Principal Investigator
United States Texas Fort Worth 76104 Texas Oncology Fort Worth at 12th Avenue
Michael A. Bookman
520-797-4468

Michael A. Bookman
Principal Investigator
United States Texas Houston 77030 The Methodist Hospital System
Aparna A. Kamat
713-790-2700

Aparna A. Kamat
Principal Investigator
United States Texas Houston 77070 Methodist Willowbrook Hospital
Aparna A. Kamat
713-790-2700

Aparna A. Kamat
Principal Investigator
United States Texas Sugar Land 77479 Houston Methodist Sugar Land Hospital
Aparna A. Kamat
713-790-2700

Aparna A. Kamat
Principal Investigator
United States Texas The Woodlands 77380 Texas Oncology-The Woodlands
Michael A. Bookman
520-797-4468

Michael A. Bookman
Principal Investigator
United States Utah Murray 84107 Intermountain Medical Center
Gregory J. Litton
801-933-6070
research@utahcancer.com

Gregory J. Litton
Principal Investigator
United States Utah Saint George 84770 Dixie Medical Center Regional Cancer Center
Gregory J. Litton
801-933-6070
research@utahcancer.com

Gregory J. Litton
Principal Investigator
United States Utah Salt Lake City 84106 Utah Cancer Specialists-Salt Lake City
Gregory J. Litton
801-933-6070
research@utahcancer.com

Gregory J. Litton
Principal Investigator
United States Virginia Charlottesville 22908 University of Virginia Cancer Center
Linda R. Duska
434-243-6322
JME3D@hscmail.mcc.virginia.edu

Linda R. Duska
Principal Investigator
United States Virginia Richmond 23298 Virginia Commonwealth University/Massey Cancer Center
William P. McGuire
443-777-7364

William P. McGuire
Principal Investigator
United States Washington Kennewick 99336 Kadlec Clinic Hematology and Oncology
Heidi J. Gray
425-899-3181

Heidi J. Gray
Principal Investigator
United States Washington Mount Vernon 98273 Skagit Valley Hospital Regional Cancer Care Center
Heidi J. Gray
425-899-3181

Heidi J. Gray
Principal Investigator
United States Washington Mount Vernon 98274 Skagit Valley Hospital
Heidi J. Gray
425-899-3181

Heidi J. Gray
Principal Investigator
United States Washington Seattle 98109 Fred Hutchinson Cancer Research Center
Heidi J. Gray
425-899-3181

Heidi J. Gray
Principal Investigator
United States Washington Seattle 98109 Seattle Cancer Care Alliance
Heidi J. Gray
425-899-3181

Heidi J. Gray
Principal Investigator
United States Washington Seattle 98133 Northwest Hospital
Heidi J. Gray
425-899-3181

Heidi J. Gray
Principal Investigator
United States Washington Seattle 98133 Women's Cancer Center of Seattle
Heidi J. Gray
425-899-3181

Heidi J. Gray
Principal Investigator
United States Washington Seattle 98195 University of Washington Medical Center
Heidi J. Gray
425-899-3181

Heidi J. Gray
Principal Investigator
United States Washington Vancouver 98686 Legacy Salmon Creek Hospital
Colleen C. McCormick
800-220-4937
cancer@lhs.org

Colleen C. McCormick
Principal Investigator
United States Washington Wenatchee 98801 Wenatchee Valley Hospital and Clinics
Heidi J. Gray
425-899-3181

Heidi J. Gray
Principal Investigator
United States West Virginia Charleston 25304 West Virginia University Charleston
Steven J. Jubelirer
304-388-9944

Steven J. Jubelirer
Principal Investigator
United States West Virginia Huntington 25701 Edwards Comprehensive Cancer Center
Maria R. Tria Tirona
304-399-6617

Maria R. Tria Tirona
Principal Investigator
United States Wisconsin Chippewa Falls 54729 Marshfield Clinic-Chippewa Center
Anthony C. Evans
800-347-0673

Anthony C. Evans
Principal Investigator
United States Wisconsin Eau Claire 54701 Marshfield Clinic Cancer Center at Sacred Heart
Anthony C. Evans
800-347-0673

Anthony C. Evans
Principal Investigator
United States Wisconsin Green Bay 54301 Saint Vincent Hospital Cancer Center Green Bay
Jonathan E. Tammela
920-433-8889
Christy.Gilchrist@hshs.org

Jonathan E. Tammela
Principal Investigator
United States Wisconsin La Crosse 54601 Gundersen Lutheran Medical Center
Lori E. Weinberg
608-775-2385
cancerctr@gundersenhealth.org

Lori E. Weinberg
Principal Investigator
United States Wisconsin Ladysmith 54848 Marshfield Clinic - Ladysmith Center
Anthony C. Evans
800-347-0673

Anthony C. Evans
Principal Investigator
United States Wisconsin Madison 53792 University of Wisconsin Hospital and Clinics
Lisa M. Barroilhet
800-622-8922

Lisa M. Barroilhet
Principal Investigator
United States Wisconsin Marshfield 54449 Marshfield Clinic
Anthony C. Evans
800-347-0673

Anthony C. Evans
Principal Investigator
United States Wisconsin Milwaukee 53226 Froedtert and the Medical College of Wisconsin
William H. Bradley
414-805-4380

William H. Bradley
Principal Investigator
United States Wisconsin Minocqua 54548 Marshfield Clinic-Minocqua Center
Anthony C. Evans
800-347-0673

Anthony C. Evans
Principal Investigator
United States Wisconsin Mukwonago 53149 ProHealth D N Greenwald Center
Timothy R. Wassenaar
262-928-7632

Timothy R. Wassenaar
Principal Investigator
United States Wisconsin Oconomowoc 53066 ProHealth Oconomowoc Memorial Hospital
Timothy R. Wassenaar
262-928-7632

Timothy R. Wassenaar
Principal Investigator
United States Wisconsin Rice Lake 54868 Marshfield Clinic-Rice Lake Center
Anthony C. Evans
800-347-0673

Anthony C. Evans
Principal Investigator
United States Wisconsin Stevens Point 54482 Marshfield Clinic Stevens Point Center
Anthony C. Evans
800-347-0673

Anthony C. Evans
Principal Investigator
United States Wisconsin Waukesha 53188 ProHealth Waukesha Memorial Hospital
Timothy R. Wassenaar
262-928-7632

Timothy R. Wassenaar
Principal Investigator
United States Wisconsin Waukesha 53188 UW Cancer Center at ProHealth Care
Timothy R. Wassenaar
262-928-7632

Timothy R. Wassenaar
Principal Investigator
United States Wisconsin Wausau 54401 Marshfield Clinic-Wausau Center
Anthony C. Evans
800-347-0673

Anthony C. Evans
Principal Investigator
United States Wisconsin Weston 54476 Marshfield Clinic - Weston Center
Anthony C. Evans
800-347-0673

Anthony C. Evans
Principal Investigator
United States Wisconsin Wisconsin Rapids 54494 Marshfield Clinic - Wisconsin Rapids Center
Anthony C. Evans
800-347-0673

Anthony C. Evans
Principal Investigator
Canada Alberta Calgary T2N 4N2 Tom Baker Cancer Centre
Prafull Ghatage
403-521-3433

Prafull Ghatage
Principal Investigator
Canada Alberta Edmonton T6G 1Z2 Cross Cancer Institute
Katia S. Tonkin
780-432-8500

Katia S. Tonkin
Principal Investigator
Canada Ontario Hamilton L8V 5C2 Juravinski Cancer Centre at Hamilton Health Sciences
Lua R. Eiriksson
905-387-9495

Lua R. Eiriksson
Principal Investigator
Canada Ontario London N6A 4L6 London Regional Cancer Program
Stephen A. Welch
519-685-8600

Stephen A. Welch
Principal Investigator
Canada Ontario Ottawa K1H 8L6 Ottawa Hospital and Cancer Center-General Campus
Michael P. Fung Kee Fung
613-761-4395

Michael P. Fung Kee Fung
Principal Investigator
Canada Ontario Sault Ste Marie P6B 0A8 Algoma District Cancer Program Sault Area Hospital
Ioannis A. Voutsadakis
705-759-3434

Ioannis A. Voutsadakis
Principal Investigator
Canada Ontario Toronto M4N 3M5 Odette Cancer Centre- Sunnybrook Health Sciences Centre
Helen J. Mackay
416-946-4501
clinical.trials@uhn.on.ca

Helen J. Mackay
Principal Investigator
Canada Ontario Toronto M5G 2M9 University Health Network-Princess Margaret Hospital
Stephanie Lheureux
416-946-4501
clinical.trials@uhn.on.ca

Stephanie Lheureux
Principal Investigator
Canada Quebec Montreal H1T 2M4 CIUSSSEMTL-Hopital Maisonneuve-Rosemont
Suzanne Fortin
514-252-3400 ext. 3329

Suzanne Fortin
Principal Investigator
Canada Quebec Montreal H2L 4M1 CHUM - Hopital Notre-Dame
Diane M. Provencher
514-890-8000 ext. 14788
marie-josee.samson.chum@ssss.gouv.qc.ca

Diane M. Provencher
Principal Investigator
Canada Quebec Montreal H3T 1E2 Jewish General Hospital
Susie K. Lau
514-340-8222 ext. 8248

Susie K. Lau
Principal Investigator
Canada Quebec Quebec City G1R 2J6 CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
Vincent Castonguay
412-339-5294
Roster@nrgoncology.org

Vincent Castonguay
Principal Investigator
Canada Quebec Sherbrooke J1H 5N4 Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
Paul Bessette
819-820-6480
crcinformation.chus@ssss.gouv.qc.ca

Paul Bessette
Principal Investigator
Japan Iwate Morioka 020-8505 Iwate Medical University School of Medicine
Satoshi Takeuchi
019-651-5111

Satoshi Takeuchi
Principal Investigator
Japan Kagoshima Kagoshima City 890-8760 Kagoshima City Hospital
Toshiaki Nakamura
011 81 099 224 2101

Toshiaki Nakamura
Principal Investigator
Japan Saitama 350-1298 Saitama Medical University International Medical Center
Hiroyuki Yoshida
81-49-276-2028

Hiroyuki Yoshida
Principal Investigator
Japan Tokyo 104 0045 National Cancer Center Hospital
Kan Yonemori
81-3-3542-2511
www-admin@ncc.go.jp

Kan Yonemori
Principal Investigator

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.